MARSEILLE, France, June 7, 2018 /PRNewswire/ --
VECT-HORUS, a biotechnology company that designs and develops vectorsfacilitating targeting of therapeutic molecules and imaging agents, announces completion of a new fund-raising round for 3.5 million euros, following a previous round of 2.5 million euros in 2017. In this new round participated
(Logo: https://mma.prnewswire.com/media/702333/Vect_Horus_Logo.jpg ) (Logo: https://mma.prnewswire.com/media/702332/Credit_Agricole_Alpes_Provence_Logo.jpg )
To view the full release click here
The proceeds of this new fund-raising will enable the company to intensify its investments in the optimization of its VECTrans®platform, to develop new molecules, particularly in the field of imaging and radiotherapy (theranostics) and forge new strategic partnerships with pharmaceutical companies.
Strengthening its investor group grants the Company significant financial resources to carry out its research and development programs. In addition, several collaboration agreements have been signed or are being negotiated with pharmaceutical partners. The Company aims to balance its R&D programs with an increasing flow of revenues from these industrial partnerships.
Damien AILLERET, Director of Corporate, Institutional and Private Banking at Crédit Agricole Alpes Provence declares "We are pleased to support VECT-HORUS in this decisive step to bring to market technologies from our territory rich in innovations in the field of health."
"We are delighted to welcome new private investors alongside our historical investors. The success of this fundraising reflects the confidence of our shareholders and validates our strategic choices as well as the future development plan of our company" says Alexandre TOKAY, President of VECT-HORUS.
Subscribe to our Free Newsletters!
Collagen plays a crucial role in glowing skin, strong nails and shiny hair. You can boost collagen ...
CRISPR technology is a simple but potent tool for editing any part of the genome (complete set of ...
FDA recently approved Mogamulizumab-kpkc, a human monoclonal antibody prescribed for adult ...View All